Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. Gibson CM, et al. Am Heart J. 2015 Apr;169(4):472-8.e5. doi: 10.1016/j.ahj.2014.12.006. Epub 2014 Dec 20. Am Heart J. 2015. PMID: 25819853 Clinical Trial.
Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
Gibson CM, Dotani MI, Murphy SA, Marble SJ, Dauterman KW, Michaels AD, Dodge JT Jr; RESTORE Investigators. Gibson CM, et al. Am Heart J. 2002 Jul;144(1):130-5. doi: 10.1067/mhj.2002.123142. Am Heart J. 2002. PMID: 12094199 Clinical Trial.
Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients.
Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E; TIMI Study Group. Gibson CM, et al. J Am Coll Cardiol. 2005 Feb 1;45(3):357-62. doi: 10.1016/j.jacc.2004.10.047. J Am Coll Cardiol. 2005. PMID: 15680712 Free article.
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E; EARLY ACS Steering Committee. Giugliano RP, et al. Among authors: gibson cm. Am Heart J. 2005 Jun;149(6):994-1002. doi: 10.1016/j.ahj.2005.03.029. Am Heart J. 2005. PMID: 15976780
809 results